Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy

Overview

About this study

The purpose of this study is:

  • To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review.
  • To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Adults (Age 18 or more years) with a diagnosis of metastatic gastric and esophageal carcinoma

Exclusion Criteria: 

  • Patients with incomplete record or if pre-treatment tissue is not available for analysis

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Harry Yoon, M.D.

Contact us for the latest status

Contact information:

Sakti Chakrabarti M.B.B.S.

(715) 735-6523

Chakrabarti.Sakti@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Harry Yoon, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Harry Yoon, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20405570

Mayo Clinic Footer